Treatment of bioresorbable scaffold failure

Bioresorbable scaffolds (BRSs) are a promising new interventional treatment strategy for coronary artery disease (CAD). They were developed to overcome some of the limitations of metal drug-eluting stents (DESs), mainly the late reinterventions that occur at a consistent rate after 1 year and have not been reduced by use of local drug-elution. Initial experience in noncomplex lesions established the efficacy in opening the vessel and the concept of bioresorption. However, with the use of BRSs in more complex lesions, also the incidence of BRSs failure, including both scaffold restenosis and thrombosis (ScT), has increased. Therefore, understanding of both the pathophysiology and of the available treatment options of scaffold failure remain important issues in ensuring procedural and long-term clinical success.

• View at Publisher
• View at Scopus